Health & bio
FDA Otarmeni Accelerated Approval 4/23 — OTOF Genetic Hearing Loss Gene Therapy
AAV vector-based lunsotogene parvec-cwha. Approvals same period: 4/21 Idvynso (HIV-1); 4/29 Langlara (insulin glargine biosimilar).
Primary sources · 1
AAV vector-based lunsotogene parvec-cwha. Approvals same period: 4/21 Idvynso (HIV-1); 4/29 Langlara (insulin glargine biosimilar).
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.